Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Investigative Dermatology

• Publication date

  1998-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/J.1523-1747.1998.00354.XPMID 9764850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

  2010cited by this paper
• Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross‐reactive autoantibodies to tyrosinase and tyrosinase‐related protein‐2 (TRP‐2)

  1997cited by this paper
• Melanoma-associated antigens as messenger RNA detection markers for melanoma.

  1997cited by this paper
• Autoantibodies to tyrosinase

  1997cited by this paper
• Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.

  1997cited by this paper
• Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine

  1997cited by this paper
• New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines

  1996cited by this paper
• Anti-tyrosinase antibodies in malignant melanoma

  1996cited by this paper
• Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.

  1996cited by this paper
• Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

  1996cited by this paper
• A melanosomal membrane protein is a cell surface target for melanoma therapy.

  1996cited by this paper
• Detection of β‐human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma

  1996cited by this paper
• Tyrosinase and related proteins in mammalian pigmentation

  1996cited by this paper
• Box 1. Autoantibodies that penetrate cells

  1996cited by this paper
• Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

  1996cited by this paper
• Melanoma and vitiligo: immunology’s Grecian urn

  1996cited by this paper
• Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma.

  1996cited by this paper
• Broken dogma: penetration of autoantibodies into living cells.

  1996cited by this paper
• Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients

  1995cited by this paper
• Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

  1995cited by this paper
• Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261]

  1995cited by this paper
• Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.

  1995cited by this paper
• Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen

  1995cited by this paper
• Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.

  1995cited by this paper
• Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

  1994cited by this paper
• Cancer antigens: immune recognition of self and altered self

  1994cited by this paper
• Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.

  1994cited by this paper
• Molecular characterization of the melanocyte lineage-specific antigen gp100.

  1994cited by this paper
• Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells.

  1994cited by this paper
• Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis.

  1994cited by this paper
• Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

  1994cited by this paper
• The role of tyrosinase in autoimmune vitiligo.

  1994cited by this paper
• Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family.

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Identification of pigment cell antigens defined by vitiligo antibodies.

  1992cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• A second tyrosinase‐related protein, TRP‐2, is a melanogenic enzyme termed DOPAchrome tautomerase.

  1992cited by this paper
• Antigen-specific CD8+ T cells switch the immune response induced by antigen from an IgG to a cell-mediated mode.

  1992cited by this paper
• A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12.

  1991cited by this paper
• The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product

  1990cited by this paper
• A cDNA encoding tyrosinase-related protein maps to the brown locus in mouse.

  1988cited by this paper
• A pigmentation‐associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum

  1983cited by this paper
• Antibodies to normal human melanocytes in vitiligo

  1983cited by this paper
• Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.

  1981cited by this paper

• Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies

  2025cites this paper
• Cutaneous manifestations associated with immune checkpoint inhibitors

  2023cites this paper
• Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors

  2022cites this paper
• Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors

  2021cites this paper
• Cutaneous adverse events caused by immune checkpoint inhibitors.

  2021cites this paper
• Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors

  2020cites this paper
• Vitíligo asociado a tratamiento inmunomodulador del melanoma metastásico

  2020cites this paper
• Characterisation of immune-modulating lymphocyte populations in melanoma patients

  2019cites this paper
• Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study

  2019cites this paper
• Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma

  2018cites this paper
• B cells and antibody production in melanoma

  2018cites this paper
• Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective study

  2017cites this paper
• Combined Intralipid-urotherapy for Patients with Cancer: A Creative Review

  2017cites this paper
• Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review

  2017cites this paper
• Intralipid-A Magic Bullet?

  2017cites this paper
• Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma

  2015cites this paper
• Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

  2015cites this paper
• A Monoclonal Antibody Against PMEL

  2014cites this paper
• Immune responses in a mouse model of vitiligo with spontaneous epidermal de‐ and repigmentation

  2014cites this paper
• The antibody response against MART‐1 differs in patients with melanoma‐associated leucoderma and vitiligo

  2014cites this paper
• Therapeutic Vaccines for Melanoma

  2012cites this paper
• Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies

  2011cites this paper
• Serum Anti-BPAG1 Auto-Antibody Is a Novel Marker for Human Melanoma

  2010cites this paper
• Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity

  2010cites this paper
• Immune/Inflammatory Aspects

  2010cites this paper
• Lentigines, nevi, and melanomas

  2010cites this paper
• A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth.

  2009cites this paper
• LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis

  2009cites this paper
• Vaccines as Targeted Cancer Therapy

  2008cites this paper
• Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

  2007cites this paper
• Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients

  2006cites this paper
• Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.

  2006cites this paper
• Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.

  2006cites this paper
• Therapeutic vaccines for melanoma: current status.

  2005cites this paper
• Molecular diagnosis of micrometastasis in the sentinel lymph node.

  2005cites this paper
• Non‐self‐discrimination as a driving concept in the identification of an immunodominant HMW‐MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients

  2004cites this paper
• Qualitative und quantitative Analyse krankheitsassoziierter MHC-Klasse-I-Liganden durch massenspektrometrische Verfahren

  2004cites this paper
• Humoral I mmune R esponse t o a T herapeutic P olyvalent C ancer Vaccine A fter C omplete R esection o f T hick P rimary M elanoma and S entinel L ymphadenectomy

  2003cites this paper
• Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.

  2003cites this paper
• DNA vaccines: an active immunization strategy for prostate cancer.

  2003cites this paper
• Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.

  2003cites this paper
• Immunotherapy of malignant melanoma.

  2003cites this paper
• A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma

  2003cites this paper
• Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: Therapeutic Utility and Implications of Nodal Microanatomy and Molecular Staging for Improving the Accuracy of Detection of Nodal Micrometastases

  2003cites this paper
• Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.

  2003cites this paper
• Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes

  2002cites this paper
• An investigation into the role of autoimmunity in vitiligo.

  2002cites this paper
• Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.

  2002cites this paper
• Melanoma

  2002cites this paper
• Melanoma Vaccines

  2002cites this paper
• Autoimmune Aspects of Vitiligo

  2001cites this paper
• Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.

  2001cites this paper
• Molecular mapping of epitopes on melanocyte‐specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo

  2001cites this paper
• Histocompatibility Complex Class II Alleles Promiscuous MAGE-A 3 Epitope Presented by Various Major Tumor-reactive T Helper Lymphocytes Recognize a Updated

  2001cites this paper
• Immunological pathomechanisms in vitiligo

  2001cites this paper
• Enhancement of anti-tumour immunity by transduction with a Mycobacterium tuberculosis gene.

  2001cites this paper
• Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients

  2000influential citation
• An overview of cancer immunotherapy

  2000cites this paper
• Vaccination for melanoma

  2000cites this paper
• Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.

  2000cites this paper
• Melanoma vaccines.

  2000cites this paper
• Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization.

  2000cites this paper
• Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccine

  1999cites this paper
• RNA Melanoma Vaccine: Induction of Antitumor Immunity by Human Glycoprotein 100 mRNA Immunization

  1999cites this paper
• High level antibody response to retrovirus‐associated but not to melanocyte lineage‐specific antigens in mice protected against B16 melanoma

  1999cites this paper